Search PubMed⌕ Search

Biomedical subjects

F Hashimoto

Publications and source records attributed to F Hashimoto.

At least 73 records · Page 4Linked to original sources
PubMed1980

Use of a semiquantitative microscopic method for detecting bacteriuria.

We evaluated a microscopic examination for bacteriuria, performed by experienced observers and by 25 house officers who were less practiced in the technique. Simulated urine samples containing known concentrations of Escherichia coli with or without polymorphonuclear leukocytes were examined uncentrifuged in a wet mount with a methylene blue stain. The experienced observers were able to determine whether a sample contained greater or less than 10(5) organisms per milliliter with a high degree of sensitivity and specificity. The house officers demonstrated a lessened discrimination, and leukocytes in the samples altered their decisions as to whether samples contained significant numbers of bacteria. Experienced observers can successfully use the microscopic examination as a rapid and inexpensive diagnostic tool to diagnose significant bacteriuria.

Bacteriuria↗
PubMed1980

Transient eosinophilia associated with pancreatitis and pseudocyst formation.

Eosinophilia is frequently associated with allergic rhinitis, asthma, drug reactions, parasitic infections, malignant neoplasms, collagen vascular diseases, skin diseases, and pulmonary infiltrates. It has been infrequently described in conjunction with pancreatic diseases and not before, to my knowledge, with pseudocyst formation. A patient with alcohol-related pancreatitis manifested a transient eosinophilia during development of a massive pancreatic pseudocyst. Although he was atopic, with a greatly elevated serum IgE level, there was no recent contact with the specific allergen to which he was sensitized. This constellation of alcohol-related pancreatitis with pseudocyst formation, atopy with elevated serum IgE level, and transient eosinophilia is an interesting coincidence.

Alcoholism↗
PubMed1979

[Clinical experience with CS-1170 in children (author's transl)].

CS-1170 was tried in children with various infections, and the following results were obtained. Some studies on the drug's pharmacokinetics were also made, and the results were as shown below: 1. The time course of serum concentration following one-shot intravenous injections of 30 mg/kg in 8 patients aged between 3 and 13 was studied. The results were: 53.4 microgram/ml, 23.4 microgram/ml, 6.6 microgram/ml, 1.8 microgram/ml and 0.5 microgram/ml at 30 minutes, 1 hour, 2 hours, 4 hours and 6 hours after the drug administration, respectively. Urinary recovery rate was 36% to 69.8% by 2 hours after, 10.9% to 70% by 2 to 4 hours after, 0.6% to 5.4% by 4 to 6 hours after the administration, and by 8 hours after the injection 91.3% of the drug was excreted in the urine. 2. Of 13 cases including 8 cases of bronchopneumonia, 2 cases of urinary tract infections, a case each of suppuration in the neck, lymphadenitis and pyothorax, CS-1170 was found to be effective in 10 cases (83.3%), while effectiveness of the drug was undeterminable in one case. 3. No remarkable side effect including allergic symptom such as eruption was observed, though transient elevation of GOT and GPT was noted in one case.

Adolescent↗
PubMed1979

[Laboratory and clinical studies on cefamandole in pediatric field (author's transl)].

Laboratory and clinical studies were performed on a new semisynthetic cephalosporin, cefamandole (CMD), and following results were obtained. (1) Serum concentrations and urinary recovery rates of CMD were determined after an intravenous administration of CMD 30 mg/kg in 13 children with normal renal function. In 5 of 13 children, mean serum levels after a one shot intravenous injection were 112.5 micrograms/ml at 15 minutes, 52.2 micrograms/ml at 30 minutes, 23.3 micrograms/ml at 1 hour, 4.9 micrograms/ml at 2 hours and trace at 4 hours. In other 5 children, mean serum levels after drip infusion for 1 hour were 78 micrograms/ml at 30 minutes, 59 micrograms/ml at 1 hour, 9.8 micrograms/ml at 2 hours and trace at 4 hours, after the onset of drip infusion. In the remaining 3 children who received CMD by drip infusion for 2 hours, mean serum levels were 24.3 micrograms/ml at 30 minutes, 35.3 micrograms/ml at 1 hour, 30.2 micrograms/ml at 2 hours, 5.3 micrograms/ml at 3 hours and 1.5 micrograms/ml at 4 hours after the onset of drip infusion. Urinary recovery rates in 5 children were 154.7%, 98.3%, 93.2%, 111.8% and 66.9%, respectively, during 8 hours. (2) CMD was administered to 40 patients with various infections (acute U.T.I. 8, acute angina lacunaris; 2, acute bronchitis; 5, cervical purulent lymphadenitis; 2, post-measles bronchopneumonia; 3, acute bronchopneumonia; 18, pyothorax; 2, S.S.S. syndrome; 1) by one-shot intravenous injection at a dose of 40-120 mg/kg per day. The clinical efficacy rate was 92.5% and bacteriological efficacy rate was 79.2%. (3) As the side effect of CMD, eosinophilia was observed in 1 case, rash and elevation of GOT and GPT in 1 case, and proteinuria in 1 case.

Adolescent↗
PubMed1978

[A clinical study of PC-904 in pediatrics (author's transl)].

A clinical study of PC-904 was performed in children. The results were as follows; 1) Serum levels of PC-904 after single administration of 20 mg/kg were studied in patients by one-shot intravenous injection or drip infusion for 1 hour or 2 hours. The results obtained in this fundamental study led to the suggestion that the proper dosage in bacterial infections would be 50 approximately 100 mg/kg intravenously in 3 approximately 4 divided doses daily. 2) A clinical study of PC-904 was performed in 16 patients including acute pharyngitis and bronchitis (3 cases), acute bronchopneumonia (3 cases), pertussis pneumonia (1 case), lymphadenitis purulenta (2 cases), acute bronchopneumonia (3 cases), pertussis pneumonia (1 case), lymphadenitis purulenta (2 cases), abscess with chronic granuloma (2 cases) and urinary tract infection (5 cases). About 50 approximately 100 mg/kg of PC-904 were administered in 3 approximately 4 divided doses daily by one-shot intravenous injection. The clinical effects of 2 cases out of 16 were impossible to be evaluated, and thses cases were excluded from the clinical evaluation. Ten cases out of 14 showed excellent or good responses (efficacy rate: 71.4%). 3) The bacteriological examinations were performed and the causative or isolated organisms were determined in 11 cases. The responses were "disappeared" in 6 cases, "decreased" in 2 cases and "not disappeared" in 3 cases. 4) No side effects were observed. Abnormalities of laboratory findings were not also noticed.

Age Factors↗